Phase I/II – First Administration

453 trials 190 recruiting

Filter these 453 trials by condition, country, sponsor and more.

Open in Search →

Investigating the safety, feasibility, and optimal dose of Adalimumab-680LT in IBD – GUIDE study Ended

2023-508391-11-00 Inflammatory Bowel Disease (IBD) 2024-03-21
Phase 1b Study to Assess the Safety, Tolerability and Pharmacodynamics of PBFT02 in Adult Participants with Frontotemporal Dementia (FTD) an… Ended

2023-507724-23-00 FRONTOTEMPORAL DEMENTIA (FTD) 2024-02-01
(VELA) Study of BLU-222 in Advanced Solid Tumors Ended

2022-502528-29-00 HR+ Breast Cancer CCNE1 Amplification HER2-negative Bre 2024-01-09
A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, an… Ended

2023-505576-29-00 Advanced solid tumors 2024-01-03
First Clinical Trial with activated regulatory T-cells in patients early after haematopoietic stem cell transplantation (HSCT) Ended

2024-516599-14-00 Leukaemia 2023-12-13
A study on the reactogenicity, safety, immune response, and efficacy of a targeted immunotherapy against HSV in healthy participants aged 18… Ended

2024-510571-37-00 Herpes Simplex 2023-12-06
First-in-human interleukin-15-transpresenting Wilms’ tumor protein 1-targeting autologous dendritic cell vaccination in cancer patients Ended

2024-515296-35-00 Histologically or cytologically confirmed solid tumor o 2023-12-06
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI 1910, a Monoclonal Antibody to… Ended

2022-503066-74-00 Advanced solid tumors 2023-12-04
A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured antiBCMA CAR T cell… Ended

2022-500782-27-00 relapsed/refractory Multiple Myeloma 2023-11-14
A Phase 1b/2 Study of BMS-986442 with Nivolumab with or without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer Ended

2022-503108-26-00 Solid Tumor 2023-11-06
A Study of NB003 in Patients With Advanced Malignancies Ended

2022-502401-15-00 Gastrointestinal stromal tumor 2023-10-19
A proof-of-concept study with NVDX3, an osteogenic implant of human allogenic origin, in the treatment of low grade degenerative lumbar spon… Ended

2023-508471-37-00 Low grade degenerative lumbar spondylolisthesis by inte 2023-10-12
Safety and efficacy of GSK Neisseria gonorrhoeae GMMA (NgG) investigational vaccine when administered to healthy adults 18 to 50 years of ag… Ended

2022-500883-37-00 This FTiH-PoC study aims to provide an early evaluation 2023-10-02
A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refr… Ended

2022-502057-33-00 Relapsed/refractory multiple myeloma 2023-10-02
APTIVATE Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with… Ended

2023-503244-14-00 Relapsed or Refractory Acute Myeloid Leukemia (AML) 2023-08-11
A first-in-human proof-of-concept study with NVDX3, an osteogenic implant of human allogenic origin, in the treatment of distal radius fract… Ended

2023-508321-27-00 Distal radius fractures 2023-08-08
Multicentric randomized phase I/IIa trial of the safety and immunogenicity of a therapeutic HPV DC targeting vaccine in patients with Human … Ended

2022-502930-25-00 reduced risk of relapse of HPV-related oropharyngeal sq 2023-07-31
A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors Ended

2023-507589-22-00 Advanced Urothelial Carcinoma and Other Solid Tumors wi 2023-07-28
A Study of TAK-676 as Single Agent and TAK-676 in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Ended

2023-505627-30-00 Solid Neoplasm 2023-07-26
A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) The… Ended

2024-513329-22-00 Lupus Nephritis 2023-07-20
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors Ended

2024-517150-10-00 Cancer 2023-06-29
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects Wi… Ended

2022-501618-70-00 BRAF-V600 Mutant Solid Tumors including Melanoma, Non-s 2023-06-27
Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors Ended

2022-500694-14-00 Head and Neck Squamous Cell Cancer 2023-06-02
A study to see how well CVGBM vaccine works at different doses and how safe it is in patients who had surgery for glioblastoma or astrocytom… Ended

2022-501423-25-00 Surgically Resected Glioblastoma (GBM) or Astrocytoma w 2023-05-05